Related Experiment Video
Updated: Dec 28, 2025
Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
Published on: June 17, 2013
Effect of Parkin on methamphetamine-induced α-synuclein degradation dysfunction in vitro and in vivo
Yunle Meng1, Honghua Qiao1,2, Jiuyang Ding1
1School of Forensic Medicine, Southern Medical University, Guangzhou, China.
Introduction:
Methamphetamine (METH) is a psychostimulant drug with complicated neurotoxicity, and abuse of METH is very common. Studies have shown that METH exposure causes alpha-synuclein (α-syn) accumulation. However, the mechanism of α-syn accumulation has not been determined.
Methods:
In this study, we established cell and animal models of METH intoxication to evaluate how METH affects α-syn expression. In addition, to explore METH-induced neurotoxicity, we measured the level of Parkin and the phosphorylation levels of α-syn, Polo-like kinase 2 (PLK2), the proteasome activity marker CD3δ, and the apoptosis-related proteins Caspase-3 and PARP. Parkin is a key enzyme in the ubiquitin-proteasome system. In addition, the effect of Parkin on METH-induced neurotoxicity was investigated by overexpressing it in vitro and in vivo.
Results:
METH exposure increased polyubiquitin and α-syn expression, as did MG132. Furthermore, the level of Parkin and the interaction between Parkin and α-syn decreased after METH exposure. Importantly, the increases in α-syn expression and neurotoxicity were relieved by Parkin overexpression.
Conclusions:
By establishing stable cell lines and animal models that overexpress Parkin, we confirmed Parkin as an important factor in METH-induced α-syn degradation dysfunction in vitro and in vivo. Parkin may be a promising target for the treatment of METH-induced neurotoxicity.
Insights
Methamphetamine (METH) abuse causes alpha-synuclein (α-syn) accumulation by impairing Parkin function. Overexpressing Parkin reduced METH-induced neurotoxicity and α-syn buildup, suggesting Parkin as a potential therapeutic target.
Area of Science:
- Neuroscience
- Toxicology
- Molecular Biology
Background:
- Methamphetamine (METH) abuse is prevalent and linked to neurotoxicity.
- METH exposure is known to cause alpha-synuclein (α-syn) accumulation.
- The precise mechanisms underlying METH-induced α-syn accumulation remain unclear.
Purpose of the Study:
- To investigate the role of Parkin in METH-induced α-syn accumulation and neurotoxicity.
- To elucidate the molecular mechanisms by which METH affects α-syn expression and degradation.
- To evaluate the therapeutic potential of Parkin in mitigating METH neurotoxicity.
Main Methods:
- Established cell and animal models of METH intoxication.
- Assessed levels of Parkin, α-syn, polyubiquitin, and apoptosis markers (Caspase-3, PARP).
- Investigated the effect of Parkin overexpression on METH-induced neurotoxicity in vitro and in vivo.
Main Results:
- METH exposure increased polyubiquitin and α-syn expression, similar to MG132 treatment.
- Parkin levels and its interaction with α-syn decreased following METH exposure.
- Overexpression of Parkin significantly reduced METH-induced increases in α-syn and neurotoxicity.
Conclusions:
- Parkin plays a critical role in the degradation of α-syn, and its dysfunction contributes to METH neurotoxicity.
- Parkin overexpression ameliorates METH-induced α-syn accumulation and neurotoxic effects.
- Parkin represents a promising therapeutic target for treating methamphetamine-induced neurotoxicity.
More Related Videos
Related Concept Videos
01:15Parkinson's Disease: Overview
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...